Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a medicinally important glycoprotein, used as an immunostimulant following bone-marrow transplant. On the basis of reports of its potential utility as an anticancer vaccine adjuvant, we undertook to develop a synthetic route toward single-glycoform GM-CSF. We describe herein a convergent total synthesis of GM-CSF aglycone and two homogeneous glycoforms. Analytical and biological studies confirm the structure and activity of these synthetic congeners.
glycoprotein synthesis | peptide ligation | alanine ligation G ranulocyte-macrophage colony-stimulating factor (GM-CSF) is a secreted glycoprotein that promotes cellular growth and proliferation. GM-CSF signaling initiates a cascade that culminates in the production of white blood cells through stem-cell stimulation in the bone marrow ( Fig. 1) (1). Therapeutically, this glycoprotein is valued for its properties as an immunostimulant; GM-CSF impacts the production, differentiation, and function of dendritic cells through potentiation of the CD4 + T-cell response (2, 3) and is regularly administered to patients undergoing chemotherapy or autologous bone-marrow transplant. GM-CSF is approved in Europe as the aglycone (Molgramostim) (4) and in the United States as a glycosylated, mutant form (Sargramostim). At present, glycosylated GM-CSF is obtained exclusively via recombinant technologies using yeast (Sargramostim) or Chinese hamster ovary (CHO) cell (Regramostim) technologies, which yield complex mixtures of glycoforms. The glycan heterogeneity reflects a lack of specificity in CHO-cell posttranslational glycosylation. The degree of GM-CSF glycosylation has been reported to affect the in vivo properties of the glycoprotein (5, 6) ; the aglycone may cause increased adverse side effects, perhaps due to its enhanced susceptibility to truncation pathways (7) .
In light of our longstanding interest in synthetic anticancer and HIV vaccines (8), we took note of reports suggesting that GM-CSF might serve as a useful vaccine immunoadjuvant. Administration of GM-CSF results in robust potentiation of the immune response, and clinical studies suggest that the glycoprotein may hold promise as an adjuvant for anticancer vaccines (9, 10) . However, studies to date have used recombinantly derived GM-CSF mixtures, and results have been inconclusive (9) ; perhaps such translational issues might be addressed in a more informative fashion with homogeneous GM-CSF agents. In a more speculative line of inquiry, we also wonder whether appendage of tumor-associated carbohydrate antigens to the protein backbone might yield powerful new anticancer vaccine candidates (11) . Even beyond these fascinating medicinal questions, we recognized in GM-CSF a synthetically compelling glycoprotein target. With these considerations in mind, we undertook to design a modular route to homogeneous GM-CSF glycoforms. In this endeavor, we would rely upon key methodological and strategic advances from many groups, including ours, in the synthesis of complex glycoproteins. The past decade has indeed witnessed a dramatic maturation of the field of "biologics" through chemical synthesis. Our recent synthesis of homogeneous erythropoietin, bearing complex glycan domains at each native position, is illustrative of the growing power of chemical synthesis to facilitate the study of medicinally relevant biologic targets (12) (13) (14) . We describe herein the synthesis of homogeneous GM-CSF glycoproteins through a convergent route that offers ready access to a menu of glycoforms for further study.
Structurally, GM-CSF consists of 127 aa with multiple sites of glycosylation (Fig. 1) . Two N-linked glycans are located at Asn 27 and Asn 37 (15, 16 , and Thr 10 ) sites of glycosylation (17) . The tertiary structure is strongly influenced by two cross-linked disulfide bonds.
Results and Discussion
Our strategy for reaching homogeneous GM-CSF constructs relies upon powerful techniques developed for the synthesis of complex biologics: namely, solid-phase peptide synthesis (SPPS), native chemical ligation (NCL), and metal-free dethiylation (MFD). Merrifield's SPPS method permits stepwise elongation of a growing peptide (18, 19) . Convergence in the construction of longer polypeptides, including small proteins, may be achieved through the use of the seminal NCL technology of Kent and coworkers, whereby fragments are merged at N-terminal cysteine residues (20, 21) . The possibility of expanding the scope of NCL to encompass, for instance, alanine ligation was demonstrated in a key paper by Yan and Dawson (22) , who accomplished dethiylation
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via Raney nickel mediation (22, 23) . In 2007, our laboratory described mild MFD conditions that enable major expansion of the menu of NCL beyond cysteine residues (24) . Thus, subsequent to cysteine-type ligation, the free thiol group may be readily removed through MFD to reveal either native alanines or a range of amino acid residues at the site of ligation (Fig. 2) .
Synthesis of the GM-CSF Aglycone
We first set out to accomplish a synthesis of the GM-CSF aglycone. We envisioned dissection of our target into four fragments, each hopefully accessible via SPPS. The key connections would include a kinetic alanine ligation between fragments 1a and 2a, as well as two cysteine ligations to join fragments 2a, 3a, and 4a ( Fig. 3) . As a critical design element, we envisioned that kinetic ligation between fragments 1a and 2a would be followed by MFD at the ligation site (Cys 34 →Ala
34
) in the presence of a thioester at the C-terminal Thr 53 residue. The cysteine residues of fragments 3a and 4a would be protected as t-butyl thioethers; the thiols would be liberated in the course of the ligation. Adoption of this approach would obviate the need for extensive protection and deprotection of the cysteines slated for "survival" in the final target.
Our synthetic vision for the GM-CSF aglycone was reduced to practice (Fig. 4) . The synthesis commenced with the preparation of fragment 3a (6 (25) . Global deprotection of the resultant peptide under modified "Cocktail B" conditions [replacing phenol with dimethyl sulfide (DMS)] afforded fragment 3a (6). In our SPPS-based route to fragment 4a (7), deblocking was conducted in a solution of 20% (vol/vol) piperidine in dimethylformamide (DMF) and 0.5 M oxyma pure (26) to avoid problematic aspartimide formation at Asp 119 -Cys 120 . Fragment 4a was obtained following global deprotection with cocktail B (2% triisopropylsilane/5% phenol/5% H 2 O/88% TFA). This general approach also provided access to fragments 1a (1) and 2a (2) , which were obtained in good yields (SI Appendix).
With the component fragments in hand, methods to accomplish their merger were evaluated (Fig. 4) . In the event, coupling of fragments 1a (1) and 2a (2) in pH 7.0 kinetic NCL buffer afforded 3. The crude reaction mixture was directly subjected to MFD. Happily, Cys 34 was smoothly reduced to Ala 34 (3→4) whereas the Thr 54 -SEt functional group remained intact. NCL of fragments 3a (6) and 4a (7) followed by treatment with MeONH 2 •HCl provided polypeptide 8 with all of the cysteine residues deprotected. The NCL-based coupling of 4 and 8 afforded the GM-CSF aglycone primary sequence (9) . Processing of construct 9, as shown in Fig. 4 , produced fully synthetic, folded GM-CSF aglycone 10.
[In one of the few papers that report yield (27) , the authors disclose a comparably low yield range, from 14-42%. That article attributes the low yield to the aggregation-prone properties of the protein. In our estimation, the modest folding yield is due to aggregation as well as unspecific binding to the folding cassette.] The properties of aglycone 10 are described in Fully Synthetic GM-CSF: Analytical Characterization and Biological Studies (28).
Synthesis of Glycosylated GM-CSF Analogs
We now directed our attention to our long-term goal of reaching single glycoform versions of GM-CSF. Although our central objective was to install glycan domains of a high-complexity order, simulating those likely to be found in glycoprotein cytokines (29), we thought it prudent to begin with a more modest level of glycosylation. In this way, we could field-test various synthetic strategies using more readily available glycans. Moreover, we hoped to gain early insights into the effect of glycosylation on stability and biofunction, while recognizing that our model constructs may not be fully comparable with cytokines bearing complex glycan domains. Thus, as a first but important step, we undertook to install chitobiose disaccharides at the two native Fig. 1 . GM-CSF 3D structure and fully glycosylated GM-CSF sequence (1). The ribbon structure of GM-CSF is based on the X-ray of GM-CSF aglycone expressed by Escherichia coli. Fig. 2 . Peptide ligation at cysteine and alanine residues. Fig. 3 . Synthetic plan for GM-CSF aglycone.
sites of N-glycosylation: Asn 27 and Asn
37
. It was envisioned that the target GM-CSF could be assembled from three fragments (1b-3b) (Fig. 5) . Fragments 1b and 2b would be prepared with the glycans installed at the wild-type sites. Notably, in contrast to the strategy adopted en route to GM-CSF aglycone, the program directed to reaching the glycosylated congeners would offer enhanced convergence; the connection between the fragments would be fashioned exclusively via "alanine ligations." Interestingly, earlier studies toward the aglycone had revealed the threefragment alanine ligation strategy to be unfeasible in that series; in the absence of N-linked carbohydrate groups, the Acm-protecting groups could not be removed (SI Appendix).
The synthesis of glycosylated GM-CSF began with the preparation of fragment 2b (Fig. 6) . The SPPS synthesis provided polypeptide 11; installation of a temporary pseudoproline group at the Glu 38 -Thr 39 position (see underline) served to effectively suppress undesired aspartimide formation at the allyl-protected Asp 37 residue (30, 31) . Selective Pd(0)-catalyzed deallylation, followed by Lansbury aspartylation (32, 33) with chitobiose, afforded glycopeptide 12. Finally, global deprotection served to liberate target fragment 2b (13) .
Fragment 3b (14) was prepared by SPPS using the oxyma pure/ piperidine deblocking protocol (26) . NCL of fragments 2b (13) and 3b (14) , followed by cleavage of the N-terminal Thz blocking group, afforded 16 in good yield (Fig. 7) . Finally, coupling of glycopeptide 16 with fragment 1b (15) provided the bis N-glycosylated GM-CSF congener 17 in excellent yield. In the penultimate step, the two cysteine-based thiol group residues (at positions 33 and 81) of 17 were subjected to MFD, thereby revealing the alanine residues of the target wild-type motif (18) . In an encouraging demonstration for future work, deprotection of the four Acm-protecting groups was readily accomplished using AgOAc (34), followed by quenching with acidic DTT. This finding is in sharp contrast, as noted above, to our inability to isolate GM-CSF aglycone following Acm removal in the last step. We can only surmise that construct 20, bearing the two glycosidic fragments, is more stable than is its aglycone domain. Processing of the fully synthetic denatured 19, as shown, afforded GM-CSF with homogeneous N-linked glycans at asparagine wild-type sites 27 and 37 (20) .
To explore potential directions as to how this chemistry might be permuted to assemble libraries of homogeneously glycosylated, wild-type GM-CSF agents, we adjusted the scheme to include only a single chitobiose domain at the Asn 37 site. This goal was readily achieved, as shown in Fig. 8 . Thus, by adopting the conditions developed in the diglycosylated series, we accomplished ligation of 16 with nonglycosylated peptide 1. Subsequent MFD, deprotection, and processing afforded the folded monoglycosylated congener, 21.
Fully Synthetic GM-CSF: Analytical Characterization and Biological Studies
We next sought to confirm that our fully synthetic materials possessed the structural and biological properties exhibited by native folded GM-CSF. Accordingly, these properties were examined in comparison with relevant commercially available samples of biotechnology-derived counterparts (Fig. 9) . The LC-MS readout of GM-CSF aglycone (10) is well aligned with that of the recombinantly derived aglycone sample ( Fig. 9 A  and B) . Figure 9C depicts an SDS/PAGE gel comparison of our synthetic samples (10, 20 , and 21) with recombinant GM-CSF aglycone and recombinant heterogeneously glycosylated GM-CSF (Leukine). The multiple bands observed in the Leukine structure reflect the mixture of glycoforms present in this material. Finally, circular dichroism (CD) spectroscopy offers further validation of the structure of our fully synthetic GM-CSF samples.
With validated fully synthetic samples of GM-CSF in hand, we undertook an in vitro biological comparison with analogous recombinantly derived materials. In these studies, the human GM-CSFdependent leukemia cell line, TF-1, was used for comparison. We were pleased to find that all three synthetic GM-CSF samples manifest a specific biological activity similar to the commercially available GM-CSF (EC 50 of ∼2.3 pg/mL) (Fig. 10A) . To further examine the effect of our synthetic GM-CSF samples on normal human hematopoietic cells, purified cord blood CD34
+ cells were cultured with human Kit ligand and in the presence or absence of various doses of recombinant GM-CSF or our synthetic GM-CSF samples (Fig. 10B) . After 14 d, colony-forming cells (CFCs) were scored. All three synthetic GM-CSF samples were capable of stimulating normal human CD34 + cells to form hematopoietic myeloid colonies in a dose-dependent manner (Fig. 10B) , and their specific biological activity was in a similar dose range (EC 50 = 0.1 ng/mL) compared with recombinant GM-CSF. This key finding provides confirmation that the material gained through synthetic means may be confidently used in preclinical biological studies directed toward immunostimulation, particularly in the adjuvant setting.
Conclusion
In summary, we have synthesized homogeneous, structurally defined GM-CSF glycoforms through a route that is in keeping with the goals of high convergence and amenability to small-library synthesis. We are encouraged to observe that the biological activity of our fully synthetic materials tracks quite closely with that obtained with recombinant GM-CSF. In addition, there are already some early indications that glycosylation, even with small domains, confers greater chemical stability to the polypeptide although this property is not yet reflected in enhanced bioperformance. Although new synthetic challenges will undoubtedly arise as the complexity level of the glycan is expanded, we are confident that the framework described herein will be adjustable to reach even more ambitious targets. 
